Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $34.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Yi Chen has given his Buy rating due to a combination of factors, primarily centered around the promising developments in RegenXBio’s pipeline. The acceptance of the Biologics License Application (BLA) for RGX-121 by the FDA with a Priority Review status is a significant milestone. This gene therapy, aimed at treating Mucopolysaccharidosis II, has the potential to address both neurodevelopmental and systemic effects of the disease, and its approval could lead to substantial commercial opportunities, including double-digit royalties and milestone payments.
Additionally, RegenXBio’s financial position is robust, with a strong cash runway extending into the second half of 2026. The company’s recent revenue figures and positive interim data from the RGX-202 trial in Duchenne muscular dystrophy further bolster confidence. The high levels of microdystrophin expression achieved in the trial are promising, suggesting potential for regulatory approval. These factors collectively support Yi Chen’s Buy rating and the $34 price target for RegenXBio’s stock.
In another report released today, Barclays also maintained a Buy rating on the stock with a $50.00 price target.